Two poster sessions at EuroPCR focus on Magmaris’ safety profile for the first cohort after three years and the full cohort subgroup analysis at one-year follow-up
Two posters presented at the EuroPCR provided new insights into the safety profile of BIOTRONIK's Magmaris® Resorbable Magnesium Scaffold (RMS). BIOSOLVE-IV study investigator Prof. Dr. Jan Torzewski, Cardiovascular Center Oberallgäu-Kempten, Germany, presented novel long-term data for the first cohort of the study. The evaluation of 1075 patients across 23 countries confirmed a good safety profile for the Magmaris RMS up to 36 months in a real-world setting. At 8.2 %, the target lesion failure rate (TLF) at 36 months1 is comparable to the low TLF rates of a contemporary DES such as Orsiro with 8.2% and Xience with 13.6% in the BIOFLOW-V trial2 over the same time period.